Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System

April 12, 2021 at 06:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Thrombectomy Device with Off-Circuit Mechanical Aspiration Design for Treatment of Undesirable Intravascular Material in Venous System and Peripheral Vasculature

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it submitted a 510(k) application to the United States Food and Drug Administration (FDA) for the AlphaVac System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the venous system and peripheral vasculature.

The AlphaVac System combines two of AngioDynamics’ proprietary technologies: a new mechanical aspiration handle and the Company’s innovative self-expanding funnel tip and is designed to provide precise control in the removal of clot burden while minimizing patient blood loss. Undesirable intravascular material can include thrombus, embolus, and vegetation found in a patient’s venous system, including the peripheral vasculature.

“We are excited to announce this important milestone in the ongoing transformation of our portfolio,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “Our team developed AlphaVac in collaboration with leading physicians to enable treatment in more cases without the need for perfusion while providing control, power and versatility to drive positive patient outcomes. AlphaVac expands our thrombus management portfolio allowing us to serve a larger, fast-growing segment of the thrombectomy market and we’re confident it will become a go-to treatment option for physicians.”

AngioDynamics anticipates the release of the AlphaVac System in the second half of calendar year 2021, subject to FDA clearance.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.

AngioDynamics and AlphaVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary.